Experimental study on efficacy of thermal muds of Ischia Island combined with balneotherapy in the treatment of psoriasis vulgaris with plaques

A lot of studies show the efficacy of thermal therapy in psoriasis. The main indications concern all forms of psoriasis (except for pustolosa and eritrodermic) especially diffuse psoriasis, intensive itchy, artropatic psoriasis and gutted psoriasis child. Benefit effects of thermal water and muds, which are important parameters in psoriasis' treatment, they are excellent to reduce inflammation, scaling, and erythema. In this study we evaluated the clinical efficacy of thermal bath plus muds in patients affected by psoriasis. 18 patients has been examined and randomly divided in 3 group (A-B-C). All the patients received thermal therapy for 4 weeks. To evaluate the behaviour of the disease we performed (corneometry, sebometry, phmetry), as well as evaluation of P.A.S.I. At the end of the study, values of P.A.S.I. showed a reduction from 10 to 6 unites P.A.S.I. for patients belong to group A, more 12 to less 10 for patients belong to group C e no significant variations for group B (because represent control group). Results obtained can be considered useful, considering that thermal treatment was used alone in the treatment of all patients.     

Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells

Intensive chemotherapy for acute myelogenous leukaemia (AML) results in an overall long-term disease-free survival of < 50%. This percentage reflects an improved survival for certain subsets of patients with low-risk cytogenetic abnormalities after treatment with high-dose cytarabine, whereas lower long-term survival is seen for other patients and especially for the large group of elderly patients. New treatment strategies are therefore considered in AML and one approach is to target the regulation of apoptosis in AML cells with new pharmacological agents. Regulation of apoptosis seems to be clinically important in AML as intracellular levels of apoptosis-regulating mediators can be used as predictors of prognosis in AML. It is also well documented that cytotoxic drugs exert important antileukaemic effects through induction of apoptosis. Marine toxins represent new pharmacological agents with proapoptotic effects and should be considered for combination therapy with cytotoxic drugs. These agents are already useful laboratory tools for in vitro studies of AML cells but it is still too early to conclude whether they will become useful in clinical therapy. One of the major problems to be investigated is the toxicity of combination therapy, although this may be solved by the coupling of toxins to antibodies or growth factors with a preferential binding to AML cells. Other problems that have to be addressed are the possible effect of the toxins' tumour promoting effects on chemosensitivity in relapsed AML and the possibility of cross-resistance between cytotoxic drugs and toxins.     

Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells

Intensive chemotherapy for acute myelogenous leukaemia (AML) results in an overall long-term disease-free survival of < 50%. This percentage reflects an improved survival for certain subsets of patients with low-risk cytogenetic abnormalities after treatment with high-dose cytarabine, whereas lower long-term survival is seen for other patients and especially for the large group of elderly patients. New treatment strategies are therefore considered in AML and one approach is to target the regulation of apoptosis in AML cells with new pharmacological agents. Regulation of apoptosis seems to be clinically important in AML as intracellular levels of apoptosis-regulating mediators can be used as predictors of prognosis in AML. It is also well documented that cytotoxic drugs exert important antileukaemic effects through induction of apoptosis. Marine toxins represent new pharmacological agents with proapoptotic effects and should be considered for combination therapy with cytotoxic drugs. These agents are already useful laboratory tools for in vitro studies of AML cells but it is still too early to conclude whether they will become useful in clinical therapy. One of the major problems to be investigated is the toxicity of combination therapy, although this may be solved by the coupling of toxins to antibodies or growth factors with a preferential binding to AML cells. Other problems that have to be addressed are the possible effect of the toxins’ tumour promoting effects on chemosensitivity in relapsed AML and the possibility of cross-resistance between cytotoxic drugs and toxins.     

Therapy for hypercholesterolemia

For most patients, hypercholesterolemia can be effectively lowered with drug therapy but only after several issues have been considered. First, drug therapy should never be considered without adequate dietary intervention. Dietary therapy may be effective for many patients with mild to moderate elevations in cholesterol. None of the drugs used to treat lipid disorders are benign agents. There is still debate about the interpretations of recent studies, the ability to generalize from studies to the whole population, and the cost effectiveness of drug treatment. Within the framework of the AHA and NCEP guidelines, an individualized approach to therapy is prudent. This should be initiated with maximal patient education because drug therapy will be maintained for the long-term or for life. The LDL and HDL levels, age, sex, other CHD risk factors, cost of treatment, patient awareness, and motivation must all be assessed when making treatment decisions. When drug therapy is considered for patients with isolated hypercholesterolemia, bile acid sequestrants are the drugs of choice.     

Anticoagulation in patients with venous thromboembolism

Deep venous thrombosis and pulmonary embolism are considered to be two variants of one disease--'venous thromboembolism'. Pathogenesis, therapy and prognosis of these both entities are very similar and therefore the term 'venous thromboembolism' has been used in recent literature. The cornerstone of therapy is anticoagulation and initially consists of heparin for at least five days. Because of pharmacokinetic advantages low molecular weight heparins are the therapy of choice. They are as efficient and save as unfractionated heparins and allow weight-adapted dosing with daily subcutaneous injections in most patients. Low molecular weight heparins do not require regularly laboratory monitoring with few exceptions, e.g. renal failure. Therefore outpatient treatment of deep venous thrombosis is possible in most patients. Although there are promising data about outpatient treatment of pulmonary embolism, this is still being studied and can not be recommended outside clinical trials. Introduction of coumarin therapy for venous thromboembolism should be started on day 1 of diagnosis, keeping the total duration of heparin therapy at no more than five days and therefore minimizing the incidence of heparin-induced thrombocytopenia. Evidence from multiple studies indicates that effective coumarin therapy in venous thromboembolism is usually reflected by an INR of 2.0 to 3.0. In patients with massive and hemodynamically relevant thromboembolism alternative therapeutic approaches such as thrombolytic therapy, thrombectomy or insertion of intravenous filters may be useful. Adequately fit compression stockings can reduce the risk of post-thrombotic syndrome after deep venous thrombosis.     

Evaluating the febrile patient with a rash

The differential diagnosis for febrile patients with a rash is extensive. Diseases that present with fever and rash are usually classified according to the morphology of the primary lesion. Rashes can be categorized as maculopapular (centrally and peripherally distributed), petechial, diffusely erythematous with desquamation, vesiculobullous-pustular and nodular. Potential causes include viruses, bacteria, spirochetes, rickettsiae, medications and rheumatologic diseases. A thorough history and a careful physical examination are essential to making a correct diagnosis. Although laboratory studies can be useful in confirming the diagnosis, test results often are not available immediately. Because the severity of these illnesses can vary from minor (roseola) to life-threatening (meningococcemia), the family physician must make prompt management decisions regarding empiric therapy. Hospitalization, isolation and antimicrobial therapy often must be considered when a patient presents with fever and a rash.     

New endoscopic hemostasis methods

Endoscopic treatment for non-variceal upper gastrointestinal bleeding has evolved over decades. Injection with diluted epinephrine is considered as a less than adequate treatment, and the current standard therapy should include second modality if epinephrine injection is used initially. Definitive hemostasis rate following mono-therapy with either thermo-coagulation or hemo-clipping compares favorably with dual therapies. The use of adsorptive powder (Hemo-spray) is a promising treatment although it needs comparative studies between hemospray and other modalities. Stronger hemo-clips with better torque control and wider span are now available. Over-the-scope clips capture a large amount of tissue and may prove useful in refractory bleeding. Experimental treatments include an endoscopic stitch device to over-sew the bleeding lesion and targeted therapy to the sub-serosal bleeding artery as guided by echo-endoscopy. Angiographic embolization of bleeding artery should be considered in chronic ulcers that fail endoscopic treatment especially in elderly patients with a major bleed manifested in hypotension.     

On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma

Randomised controlled trials (RCTs) with sufficiently high statistical power are not always feasible for patients when the administration of the treatment is burdensome. Nevertheless, useful information concerning the relative effectiveness of the Test and Standard therapies, may be gleaned from under powered trials, non-randomised comparative studies and/or clinician's beliefs: the latter possibly additionally providing some suggestion of the strength of evidence required in order to adopt the Test therapy into clinical practice. In such circumstances, a Bayesian synthesis may be useful in quantifying the evidence of treatment effectiveness. In this article, we aim to present a Bayesian approach for synthesizing the cumulative evidence of the use of adjuvant hepatic intra-arterial iodine-131-lipiodol (I131L) following curative resection in hepatocellular carcinoma (HCC) patients. We constructed a posterior distribution using the information from two small RCTs, three non-randomised comparative studies, three single arm studies and the views of investigators on the use of I131L. This distribution enables calculation of the probability that the Test therapy is more effective than the Standard by a pre-stipulated amount. If this is very high, then for example, one may conclude the Test may replace the Standard therapy. If it is not, then the Standard would be retained for clinical use. Despite a strong early indication of the effectiveness of I131L, the evolving evidence over a 10-year period became more sceptical of its value. Although highly recommended, difficulties of implementing a Bayesian approach in this context are highlighted.     

Nettle sting of Urtica dioica for joint pain--an exploratory study of this complementary therapy

This exploratory study aims to explore the present use of the common stinging nettle to treat joint pain. Eighteen self-selected patients using the nettle sting of Urtica dioica were interviewed. Information regarding patients' use of nettle therapy was elicited, in particular mode of application, dosage and effects. All except one respondent were sure that netles had been very helpful and several considered themselves cured. No observed side effects were reported, except a transient urticarial rash. This exploratory study suggests nettle sting is a useful, safe and cheap therapy which needs further study. A randomized controlled trial is planned in collaboration with a rheumatology specialist.     

The importance of tricuspid regurgitation and right ventricular overload in ICD/CRT recipients: beside the left, beyond the left

Device therapy for advanced heart failure has become increasingly employed in the last 10 years. Several retrospective studies have postulated a harmful effect of implantable cardioverter-defibrillator (ICD) lead placement on tricuspid valve function and right heart hemodynamics, in particular among patients with preexisting pulmonary vascular overload and both left and right ventricular remodeling/dysfunction. This functional hypothesis is also supported by long-term clinical follow-up analyses of ICD and cardiac resynchronization therapy recipients. In this viewpoint, we propose that the possibility of worsening tricuspid regurgitation and consequent hemodynamic deterioration following device implantation should be considered in future studies, as well as in the preimplant evaluation of individual candidates among other clinical factors.     

Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3

On-treatment predictors of response could be useful in optimizing treatment for patients with hepatitis C virus (HCV) genotype 2 or 3. Early virological response (EVR) has limited value as a predictor of response in genotype 2 or 3 patients, as it is achieved by 97% of this population. However, rapid virological response (RVR) measured at week 4 is a strong predictor of sustained virological response (SVR) in this group, and patients achieving an RVR may be suitable candidates for shorter treatment durations. Several small studies investigating the efficacy of shortened treatment durations in this population have been published; however, differences in study design have made their collective interpretation difficult. We discuss these studies, followed by a comparison of the data from ACCELERATE, the largest, randomized trial carried out to investigate abbreviated therapy in genotype 2 and 3 patients. The data confirm that RVR, and its use alongside significant baseline predictors, can assist in optimizing therapy. Patients achieving an RVR have high SVR rates and might be candidates for shorter treatment duration, particularly those displaying a low viral load at baseline; however, the need to consider the increased rate of relapse versus the benefits of abbreviated therapy must also be considered. Conversely, in patients who do not achieve an RVR there is evidence to suggest they may benefit from intensified therapy (longer therapy and/or increased doses). As in genotype 1 and 4 patients, response-guided therapy aims to optimize treatment outcomes for individuals, without compromising SVR rates.     

Osteoporosis in women with spinal cord injuries

Decreased bone density and increased fracture risk are seen in patients with SCI. The bone resorption rate is markedly increased. Hypercalciuria, low PTH, and low 1,25 (OH)2 vitamin D are commonly seen. Bed-rest studies show similar findings, but of lesser magnitude. Therapies to treat or prevent osteoporosis include optimal nutrition (with care to avoid exacerbating hypercalciuria). Weight-bearing or functional electrical stimulation cycle ergometry may prevent some of the bone loss, especially in acutely injured patients. Estrogen should be considered in postmenopausal or amenorrheic women, but not if they are at high risk of thromboembolism. More research on effects of estrogen is needed in this population. Bisphosphonates may also help prevent the acute bone loss; oral routes must not be used in recumbent patients. Thiazides could be useful as adjunct therapy.     

Drug Therapy for Survivors of Sudden Cardiac Death

The proliferation of standard as well as novel community based systems for resuscitation of victims of out-of-hospital cardiac arrest has provided a large group of sudden cardiac death survivors who present a therapeutic challenge. The nature and severity of the underlying heart disease must be delineated. Particularly, myocardial ischemia and congestive heart failure must be controlled. Prior to considering device therapy of surgical intervention, pharmacologic therapy should be evaluated. Baseline electrophysiological studies determine the applicability of serial pharmacologic testing. In patients with inducible VT/VF, serial electrophysiological testing can identify drug regimens that prevent the arrhythmia in approximately 40% of patients. In an additional 20% of patients, regimens which slow the ventricular tachycardia and significantly reduce the arrhythmia related mortality can be identified. Three to 5-year follow-up has shown such an approach can reduce the sudden death mortality in these patients to less than 3% per year. It has been suggested that certain medication, most notably amiodarone, electrophysiological testing has not been useful in assessing efficacy. Several recent studies, however, have shown that electrophysiological testing is indeed useful even in evaluating the efficacy of amiodarone. In patients in whom ventricular tachycardia/ventricular fibrillation cannot be prevented or significantly slowed, medical therapy is generally ineffective and the sudden death mortality is 20% to 40% per year. In such patients, other therapeutic modalities should be considered.     

First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study

Aims: Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON), a global, non‐interventional, surveillance study, aims to evaluate the safety of sorafenib in all patients with unresectable hepatocellular carcinoma (uHCC) under real‐life practice conditions, particularly Child‐Pugh B patients, who were not well represented in clinical trials. Methods: Treatment decisions are determined by each physician according to local prescribing guidelines and clinical practice. Patients with uHCC who are candidates for systemic therapy, and for whom a decision has been made to treat with sorafenib, are eligible for inclusion. Demographic data and medical and disease history are recorded at entry. Sorafenib dosing and adverse events (AEs) are collected throughout the study. Results: From January 2009 to April 2011, >3000 patients from 39 countries were enrolled. The prespecified first interim analysis was conducted when the initial approximately 500 treated patients had been followed up for ≥4 months; 479 were valid for safety evaluation. Preplanned subgroup analyses indicate differences in patient characteristics, disease aetiology and previous treatments by region. Variation in sorafenib dosing by specialty are also observed; Child‐Pugh status did not appear to influence the starting dose of sorafenib. The type and incidence of AEs was consistent with findings from previous clinical studies. AE profiles were comparable between Child‐Pugh subgroups. Discussion: The GIDEON study is generating a large, robust database from a broad population of patients with uHCC. First interim analyses have shown global and regional differences in patient characteristics, disease aetiology and practice patterns. Subsequent planned analyses will allow further evaluation of early trends.     

Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic drugs that improve glycemic control without causing weight gain or increasing hypoglycemic risk in patients with type 2 diabetes (T2DM). The efficacy and tolerability of saxagliptin, a once-daily DPP-4 inhibitor, administered as monotherapy, as add-on therapy to metformin, a sulfonylurea, or a thiazolidinedione, and as initial combination therapy with metformin, was demonstrated in pivotal 24-week clinical trials. Additional information about the clinical profile of saxagliptin was recently obtained from extension studies, head-to-head clinical trials, and post-hoc analyses. In extension studies, the efficacy and tolerability of add-on saxagliptin and initial saxagliptin-plus-metformin therapy were maintained for up to 102 weeks. Saxagliptin plus metformin was shown to be non-inferior to glipizide plus metformin in lowering glycated hemoglobin from base-line, with reduced body-weight and lower hypoglycemic risk. Post-hoc analyses indicate that the clinical benefits of saxagliptin extend across demographic subgroups and special populations. A meta-analysis found no evidence for increased cardiovascular risk in T2DM patients exposed to saxagliptin for > 1 year. On the basis of this clinical profile, saxagliptin is an attractive option for initial and add-on therapy for T2DM patients with inadequate glycemic control.     

Medical therapy in ulcerative colitis

Salazosulfapyridine(SASP) and 5-aminosalicyclic acid(5-ASA) are useful in the therapy of mildly to moderately active ulcerative colitis. 5-ASA lacks sulfa moiety of SASP and is associated with a decreased incidence of side effects. In patients with moderate or severe ulcerative colitis, glucocorticoids which may be given in conjunction with SASP or 5-ASA are beneficial in producing remission. Proctitis or left-sided colitis is effectively treated with glucocorticoid enemas. If symptoms are refractory to outpatient management, the patient should be hospitalized and given initial therapy with glucocorticoids. Total colectomy(ileo-anal anastomosis; IAA et al) must be considered for acutely ill patients not responding to intensive medical therapy. Early surgical consultation is necessary in severely ill patients.     

Evidence-based medicine and sleep apnea.

There is an increasing body of evidence that obstructive sleep apnea (OSA) affects systemic blood pressure and quality of life. The evidence linking OSA with other types of cardiovascular morbidity and mortality is not as strong. We review the current literature on the health impact, diagnosis, and treatment of OSA and provide a framework for evaluating levels of evidence in each of these areas, with the focus on high quality studies. Clinical prediction rules and unattended portable monitoring devices, such as digital oximeters, are inexpensive and have clinically useful likelihood ratios, sensitivity, and specificity, so they can be considered clinically useful in the evaluation of individuals suspected of having OSA. This approach has the potential to change the probability of disease in some patients to a level at which polysomnography is unnecessary. Recent randomized, placebo-controlled trials have indicated that treating OSA with continuous positive airway pressure improves quality of life, driving simulator performance, blood pressure, and sleepiness. The evidence in support of mandibular advancement is less strong, and surgical measures should be viewed as an option only after continuous positive airway pressure and mandibular advancement have been considered, given the paucity of evidence to support surgery. The quality of research done on the prognosis, diagnosis, and treatment of OSA has improved substantially in recent years. However, there remains a need for additional studies that evaluate ambulatory monitors and for larger randomized controlled trials of therapy with longer patient follow-up to verify the range of benefits that OSA patients can expect from the various treatment modalities.     

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment

BACKGROUND: Oral bisphosphonates are routinely prescribed for the treatment of postmenopausal osteoporosis. In clinical trials, oral bisphosphonates have been found to increase bone mineral density (BMD) and decrease fracture risk in the majority of the treated population. However, in both clinical trials and clinical practice, not all patients experience significant increases in BMD. In clinical trials, nonresponse is often defined as a BMD change of 相似文献   

Evaluation of acute chest pain syndromes by two-dimensional echocardiography: its potential application in the selection of patients for acute reperfusion therapy

Two-dimensional echocardiography is useful for the immediate diagnosis of acute myocardial infarction when diagnostic electrocardiographic changes are absent. The technique is also helpful in distinguishing myocardial infarction from other conditions that may clinically or electrocardiographically mimic infarction. The extent of myocardial infarction can be estimated by the two-dimensional echocardiographically derived wall motion score index. Therefore, two-dimensional echocardiography seems to be ideally suited for the initial noninvasive assessment of patients with acute chest pain syndromes, especially those who are considered for acute reperfusion therapy.     

Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study

BACKGROUND: The optimal treatment regimen for eradication of Helicobacter pylori in patients with duodenal ulcer has yet to be determined. Based on a search of MEDLINE, no studies have been performed comparing a proton pump inhibitor-based triple therapy regimen with a ranitidine bismuth citrate (RBC)-based dual therapy regimen, both containing clarithromycin. OBJECTIVE: This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer. METHODS: Patients were randomized to receive either 1 week of triple therapy with LAN 30 mg BID, clarithromycin 500 mg BID, and tinidazole 500 mg BID, followed by 3 weeks of LAN 30 mg BID, or 2 weeks of dual therapy with RBC 400 mg BID plus clarithromycin 500 mg BID, followed by 2 weeks of RBC 400 mg BID. Eradication of H pylori was defined as negative results on both the urease quick test and histologic examination > or =4 weeks after the end of treatment. Duodenal healing and recurrence rates were assessed endoscopically at 8 weeks and 6 months. A per-protocol (PP) analysis was conducted for each efficacy end point. Also conducted were an intent-to-treat (ITT) analysis in which patients with missing data were considered failures, and an observed analysis (OBS), which included patients with an evaluable result after treatment, regardless of compliance. RESULTS: One hundred eighty-five patients (126 men, 59 women; age range, 18-76 years; mean age, 43 years) were enrolled and randomized to treatment. In the LAN and RBC groups, respectively, H. pylori eradication rates were 92.6%, 93.1%, and 72.8% versus 78.6%, 77.9%, and 64.5% in the PP (P = 0.02), OBS (P = 0.01), and ITT analyses. The corresponding duodenal ulcer healing rates were 98.6%, 98.7%, and 83.7% versus 90.8%, 91.5%, and 81.7%; these differences were not statistically significant. Side effects were mild, occurring in 20.7% of LAN patients and 17.2% of RBC patients. Ulcer recurred in 2 RBC patients. No difference was observed between treatments in terms of the occurrence of gastritis or improvement of symptoms. CONCLUSION: Based on the results of the PP and OBS analyses, LAN-based triple therapy was superior to RBC-based dual therapy for the eradication of H. pylori in patients with duodenal ulcer.